刚刚，同仁堂道歉！

Core Viewpoint - The company is taking immediate and strict actions to protect its brand and consumer rights in response to allegations of false advertising related to a product marketed under its name. Group 1: Brand Protection Measures - The company has initiated a zero-tolerance brand management action, which includes legal accountability for trademark infringement against Sichuan Health, Habo Pharmaceutical, and related e-commerce platforms for misleading consumers [1] - A comprehensive investigation into brand usage violations across all subsidiaries is being conducted to ensure compliance with brand management standards [1] - The company is enforcing strict regulations on e-commerce platform store identifiers to ensure accurate representation of its brand and products [1] Group 2: Response to Allegations - Following allegations of false labeling of a product claiming to contain high levels of phospholipids, the company clarified that the involved entity, Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., is not a subsidiary of the company [4] - The company has dispatched a special task force to Sichuan to conduct a thorough investigation into the product in question and has mandated the immediate removal of the product from shelves [5] - The company emphasizes that it focuses on the production and sale of its own pharmaceutical products, with no outsourcing to third parties, ensuring the integrity of its offerings [9]